Short answer

Assembly Biosciences Inc (ASMB) filed its fiscal 2013 10-K annual report with the SEC on Mar 31, 2014.

Top risk flagged: FDA could require a second U.S. study for VEN 307 after February 2014 Phase III failure

Assembly Biosciences Inc FY2013 10-K analysis

AI summary of each section, grounded in the filing text

Development-stage specialty pharmaceutical model, repurposing approved molecules for gastrointestinal indications through 505(b)(2) pathways
New VEN 310 platform licensed in November 2013, enabling pH-targeted colonic delivery of bacteria, proteins, vaccines and small molecules
Strategic expansion from two topical products toward microbiome and targeted-delivery opportunities, including in-licensing and acquisitions
VEN 307 systemic exposure approximately 10% of oral diltiazem, supporting a potentially high safety margin
VEN 307 Phase III safety and PK results were positive, but the 400-subject pivotal trial failed its primary pain endpoint
Year-end operating footprint: 10 employees and six consultants as of February 28, 2014

No product revenue in 2013 or 2012, development-stage company
Net loss $19.4M in 2013, R&D expense $15.0M, down 22.98% from $19.5M
VEN 307 best-funded program, 2013 R&D $14.6M vs VEN 310 $358,250 and VEN 309 $(585,347)
Operating cash use $17.8M, investing cash use $6,477, financing cash provided $24.4M
No buybacks or dividends, cash expected through Q2 2016; FDA approval and launch targeted for second half 2015

FDA could require a second U.S. study for VEN 307 after February 2014 Phase III failure
Foreign contract manufacturers exposed to shipping delays and import restrictions
VEN 307 license concentration: $41,500 monthly S.L.A. Pharma fees and up to $20 million milestones
Competition from FDA-approved Rectiv and Solesta, plus two non-drug products in development
Key-person dependency: CEO and acting CMO Dr. Russell H. Ellison, without retention assurance or key-man insurance

Generated from the filing text; verify against the original. How to read a 10-K

Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.